ORLANDO, Fla., April 4, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced results from a preclinical study of C2-2b-2b, a new protein construct created by the Company's proprietary Dock-and-Lock method (DNL) for protein engineering. C2-2b-2b is an immunocytokine comprising 4 molecules of interferon-alpha-2b (IFNa2b) fused to the humanized antibody, IMMU-114, that targets the HLA-DR antigen.
